An exploratory biomarker study of immunecheckpoint inhibitors using tumor tissue and peripheral blood

Trial Profile

An exploratory biomarker study of immunecheckpoint inhibitors using tumor tissue and peripheral blood

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 26 Oct 2017 Results (n=34, Data cut off March 2017) of a study assessing IL-8, TNF-alpha, and VEGF-A as potential biomarkers to predict clinical benefit presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 26 Oct 2017 Results (n=38) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 18 Oct 2017 Results (n=38) assessing relation between immune related adverse events and efficacy, presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top